MIMEDX GROUP INC (MDXG) Stock Fundamental Analysis
USA - NASDAQ:MDXG - US6024961012 - Common Stock
7.02 USD
-0.13 (-1.82%)
7.02 USD
0 (0%)
MDXG gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 540 industry peers in the Biotechnology industry. MDXG has an excellent financial health rating, but there are some minor concerns on its profitability. MDXG has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
MDXG had positive earnings in the past year.
In the past year MDXG had a positive cash flow from operations.
In multiple years MDXG reported negative net income over the last 5 years.
The reported operating cash flow has been mixed in the past 5 years: MDXG reported negative operating cash flow in multiple years.
1.2 Ratios
MDXG has a Return On Assets of 11.05%. This is amongst the best in the industry. MDXG outperforms 93.89% of its industry peers.
With an excellent Return On Equity value of 14.85%, MDXG belongs to the best of the industry, outperforming 94.07% of the companies in the same industry.
MDXG has a better Return On Invested Capital (13.37%) than 95.37% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.05% | ||
| ROE | 14.85% | ||
| ROIC | 13.37% |
ROA(3y)4.7%
ROA(5y)-7.18%
ROE(3y)1.74%
ROE(5y)-20.73%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
MDXG has a better Profit Margin (8.84%) than 91.85% of its industry peers.
MDXG has a better Operating Margin (12.07%) than 92.78% of its industry peers.
MDXG's Operating Margin has been stable in the last couple of years.
Looking at the Gross Margin, with a value of 81.45%, MDXG belongs to the top of the industry, outperforming 85.19% of the companies in the same industry.
MDXG's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 12.07% | ||
| PM (TTM) | 8.84% | ||
| GM | 81.45% |
OM growth 3YN/A
OM growth 5Y-1.06%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.19%
GM growth 5Y-0.67%
2. Health
2.1 Basic Checks
MDXG has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
The number of shares outstanding for MDXG has been increased compared to 1 year ago.
Compared to 5 years ago, MDXG has more shares outstanding
The debt/assets ratio for MDXG has been reduced compared to a year ago.
2.2 Solvency
MDXG has an Altman-Z score of 10.61. This indicates that MDXG is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of MDXG (10.61) is better than 85.93% of its industry peers.
MDXG has a debt to FCF ratio of 0.32. This is a very positive value and a sign of high solvency as it would only need 0.32 years to pay back of all of its debts.
MDXG has a Debt to FCF ratio of 0.32. This is amongst the best in the industry. MDXG outperforms 95.93% of its industry peers.
A Debt/Equity ratio of 0.08 indicates that MDXG is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.08, MDXG is doing worse than 62.96% of the companies in the same industry.
Even though the debt/equity ratio score it not favorable for MDXG, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.08 | ||
| Debt/FCF | 0.32 | ||
| Altman-Z | 10.61 |
ROIC/WACC1.39
WACC9.62%
2.3 Liquidity
MDXG has a Current Ratio of 4.39. This indicates that MDXG is financially healthy and has no problem in meeting its short term obligations.
MDXG has a Current ratio (4.39) which is in line with its industry peers.
A Quick Ratio of 3.90 indicates that MDXG has no problem at all paying its short term obligations.
MDXG has a Quick ratio of 3.90. This is comparable to the rest of the industry: MDXG outperforms 46.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.39 | ||
| Quick Ratio | 3.9 |
3. Growth
3.1 Past
MDXG shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -54.39%.
Looking at the last year, MDXG shows a small growth in Revenue. The Revenue has grown by 6.85% in the last year.
Measured over the past years, MDXG shows a small growth in Revenue. The Revenue has been growing by 3.11% on average per year.
EPS 1Y (TTM)-54.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.67%
Revenue 1Y (TTM)6.85%
Revenue growth 3Y10.5%
Revenue growth 5Y3.11%
Sales Q2Q%13.07%
3.2 Future
Based on estimates for the next years, MDXG will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.23% on average per year.
MDXG is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 12.54% yearly.
EPS Next Y14.31%
EPS Next 2Y9.89%
EPS Next 3Y15.23%
EPS Next 5YN/A
Revenue Next Year11.61%
Revenue Next 2Y9.88%
Revenue Next 3Y10.48%
Revenue Next 5Y12.54%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 27.00 indicates a quite expensive valuation of MDXG.
Based on the Price/Earnings ratio, MDXG is valued cheaper than 93.15% of the companies in the same industry.
When comparing the Price/Earnings ratio of MDXG to the average of the S&P500 Index (27.41), we can say MDXG is valued inline with the index average.
The Price/Forward Earnings ratio is 20.05, which indicates a rather expensive current valuation of MDXG.
92.59% of the companies in the same industry are more expensive than MDXG, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of MDXG to the average of the S&P500 Index (22.88), we can say MDXG is valued inline with the index average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 27 | ||
| Fwd PE | 20.05 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, MDXG is valued cheaply inside the industry as 94.26% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, MDXG is valued cheaper than 94.81% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 18.09 | ||
| EV/EBITDA | 17.59 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates MDXG does not grow enough to justify the current Price/Earnings ratio.
The decent profitability rating of MDXG may justify a higher PE ratio.
MDXG's earnings are expected to grow with 15.23% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.89
PEG (5Y)N/A
EPS Next 2Y9.89%
EPS Next 3Y15.23%
5. Dividend
5.1 Amount
MDXG does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
7.02
-0.13 (-1.82%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners70.37%
Inst Owner Change2.4%
Ins Owners1.84%
Ins Owner Change0.62%
Market Cap1.04B
Analysts81.82
Price Target12.44 (77.21%)
Short Float %3.43%
Short Ratio6.65
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)44.25%
Min EPS beat(2)6.95%
Max EPS beat(2)81.55%
EPS beat(4)3
Avg EPS beat(4)17%
Min EPS beat(4)-31.92%
Max EPS beat(4)81.55%
EPS beat(8)7
Avg EPS beat(8)68.99%
EPS beat(12)10
Avg EPS beat(12)59.73%
EPS beat(16)12
Avg EPS beat(16)49.94%
Revenue beat(2)2
Avg Revenue beat(2)3.5%
Min Revenue beat(2)0.32%
Max Revenue beat(2)6.68%
Revenue beat(4)3
Avg Revenue beat(4)2.13%
Min Revenue beat(4)-0.35%
Max Revenue beat(4)6.68%
Revenue beat(8)6
Avg Revenue beat(8)1.52%
Revenue beat(12)8
Avg Revenue beat(12)2.12%
Revenue beat(16)12
Avg Revenue beat(16)2.46%
PT rev (1m)0%
PT rev (3m)1.67%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-15.15%
EPS NY rev (1m)28.71%
EPS NY rev (3m)32.11%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.38%
Revenue NY rev (1m)2.85%
Revenue NY rev (3m)2.85%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 27 | ||
| Fwd PE | 20.05 | ||
| P/S | 2.86 | ||
| P/FCF | 18.09 | ||
| P/OCF | 17.87 | ||
| P/B | 4.79 | ||
| P/tB | 5.61 | ||
| EV/EBITDA | 17.59 |
EPS(TTM)0.26
EY3.7%
EPS(NY)0.35
Fwd EY4.99%
FCF(TTM)0.39
FCFY5.53%
OCF(TTM)0.39
OCFY5.6%
SpS2.46
BVpS1.46
TBVpS1.25
PEG (NY)1.89
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.05% | ||
| ROE | 14.85% | ||
| ROCE | 18.24% | ||
| ROIC | 13.37% | ||
| ROICexc | 26.4% | ||
| ROICexgc | 35.58% | ||
| OM | 12.07% | ||
| PM (TTM) | 8.84% | ||
| GM | 81.45% | ||
| FCFM | 15.78% |
ROA(3y)4.7%
ROA(5y)-7.18%
ROE(3y)1.74%
ROE(5y)-20.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5Y-47.46%
ROICexc growth 3YN/A
ROICexc growth 5Y-21.46%
OM growth 3YN/A
OM growth 5Y-1.06%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.19%
GM growth 5Y-0.67%
F-Score5
Asset Turnover1.25
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.08 | ||
| Debt/FCF | 0.32 | ||
| Debt/EBITDA | 0.32 | ||
| Cap/Depr | 6.78% | ||
| Cap/Sales | 0.2% | ||
| Interest Coverage | 28.3 | ||
| Cash Conversion | 106.77% | ||
| Profit Quality | 178.44% | ||
| Current Ratio | 4.39 | ||
| Quick Ratio | 3.9 | ||
| Altman-Z | 10.61 |
F-Score5
WACC9.62%
ROIC/WACC1.39
Cap/Depr(3y)52.31%
Cap/Depr(5y)58.09%
Cap/Sales(3y)0.72%
Cap/Sales(5y)1.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-54.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.67%
EPS Next Y14.31%
EPS Next 2Y9.89%
EPS Next 3Y15.23%
EPS Next 5YN/A
Revenue 1Y (TTM)6.85%
Revenue growth 3Y10.5%
Revenue growth 5Y3.11%
Sales Q2Q%13.07%
Revenue Next Year11.61%
Revenue Next 2Y9.88%
Revenue Next 3Y10.48%
Revenue Next 5Y12.54%
EBIT growth 1Y-29.45%
EBIT growth 3YN/A
EBIT growth 5Y2.02%
EBIT Next Year32.1%
EBIT Next 3Y17.11%
EBIT Next 5YN/A
FCF growth 1Y1521.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y6349.89%
OCF growth 3YN/A
OCF growth 5YN/A